184 related articles for article (PubMed ID: 22511370)
21. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
22. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
[TBL] [Abstract][Full Text] [Related]
23. Targeting the hedgehog pathway to treat basal cell carcinoma.
Geeraert P; Williams JS; Brownell I
J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
[TBL] [Abstract][Full Text] [Related]
24. Basosquamous carcinoma and metatypical basal cell carcinoma: a review of treatment with Mohs micrographic surgery.
Allen KJ; Cappel MA; Killian JM; Brewer JD
Int J Dermatol; 2014 Nov; 53(11):1395-403. PubMed ID: 24961583
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
[TBL] [Abstract][Full Text] [Related]
26. Signaling Pathways and Therapeutic Strategies in Advanced Basal Cell Carcinoma.
Vallini G; Calabrese L; Canino C; Trovato E; Gentileschi S; Rubegni P; Tognetti L
Cells; 2023 Oct; 12(21):. PubMed ID: 37947611
[TBL] [Abstract][Full Text] [Related]
27. The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment.
Caro I; Low JA
Clin Cancer Res; 2010 Jul; 16(13):3335-9. PubMed ID: 20439455
[TBL] [Abstract][Full Text] [Related]
28. Metastatic spinal cord compression from basal cell carcinoma of the skin treated with surgical decompression and vismodegib: case report and review of Hedgehog signalling pathway inhibition in advanced basal cell carcinoma.
McGrane J; Carswell S; Talbot T
Clin Exp Dermatol; 2017 Jan; 42(1):80-83. PubMed ID: 27905158
[TBL] [Abstract][Full Text] [Related]
29. Small molecule inhibitors of the hedgehog signaling pathway for the treatment of cancer.
Yun JI; Kim HR; Park H; Kim SK; Lee J
Arch Pharm Res; 2012 Aug; 35(8):1317-33. PubMed ID: 22941475
[TBL] [Abstract][Full Text] [Related]
30. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
31. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease.
McCusker M; Basset-Seguin N; Dummer R; Lewis K; Schadendorf D; Sekulic A; Hou J; Wang L; Yue H; Hauschild A
Eur J Cancer; 2014 Mar; 50(4):774-83. PubMed ID: 24412051
[TBL] [Abstract][Full Text] [Related]
32. Molecular testing in metastatic basal cell carcinoma.
Verkouteren BJA; Wakkee M; van Geel M; van Doorn R; Winnepenninckx VJ; Korpershoek E; Mooyaart AL; Reyners AKL; Terra JB; Aarts MJB; Reinders MGHC; Mosterd K
J Am Acad Dermatol; 2021 Nov; 85(5):1135-1142. PubMed ID: 31870915
[TBL] [Abstract][Full Text] [Related]
33. Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma.
Otsuka A; Dreier J; Cheng PF; Nägeli M; Lehmann H; Felderer L; Frew IJ; Matsushita S; Levesque MP; Dummer R
Clin Cancer Res; 2015 Mar; 21(6):1289-97. PubMed ID: 25593302
[TBL] [Abstract][Full Text] [Related]
34. Clinical experience with Hedgehog pathway inhibitors.
Low JA; de Sauvage FJ
J Clin Oncol; 2010 Dec; 28(36):5321-6. PubMed ID: 21041712
[TBL] [Abstract][Full Text] [Related]
35. Case of metastatic basal cell carcinoma to bone marrow, resulting in myelophthisic anemia.
Pham CM; Syed AA; Siddiqui HA; Keller RA; Kowalewski C
Am J Dermatopathol; 2013 Apr; 35(2):e34-6. PubMed ID: 23147353
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous basal cell carcinoma with distant metastasis to thorax and bone : A clinicopathological and immunohistochemical study of 15 cases.
Weissferdt A; Kalhor N; Moran CA
Virchows Arch; 2017 Jun; 470(6):687-694. PubMed ID: 28391557
[TBL] [Abstract][Full Text] [Related]
37. Metastatic basal cell carcinoma: a frequent disease with rare clinical evolution.
Carvalho CT; Pinto MM; Plácido AN; Martins A
BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25911359
[TBL] [Abstract][Full Text] [Related]
38. Cemiplimab for locally advanced and metastatic basal cell carcinoma.
Damsin T; Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2022 Mar; 22(3):243-248. PubMed ID: 35175882
[TBL] [Abstract][Full Text] [Related]
39. The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997-2010.
Nguyen-Nielsen M; Wang L; Pedersen L; Olesen AB; Hou J; Mackey H; McCusker M; Basset-Seguin N; Fryzek J; Vyberg M
Eur J Dermatol; 2015; 25(5):463-8. PubMed ID: 26105129
[TBL] [Abstract][Full Text] [Related]
40. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
